Publication

EAHAD •
7 February, 2025 •
•

Efanesoctocog Alfa for the Perioperative Management of Patients with Severe Haemophilia A: 4 years of Experience in the XTEND Clinical Program

Anthony K. C. Chan, Flora Peyvandi, Annette von Drygalski, Sandrine Meunier, Elena Santagostino, Linda Bystrická, Jennifer Dumont , Lara Mamikonian, Umer Khan, Liane Khoo, Robert Klamroth

Available materials

Oral Presentation

Publication

EAHAD •
7 February, 2025 •
•

Two-Year Clinical Outcomes of Once-Weekly Efanesoctocog Alfa Prophylaxis in Children with Severe Hemophilia A: Second Interim Analysis of the XTEND-ed Phase 3 Study

Lynn Malec, Beatrice Nolan, Anthony K. C. Chan, Manuela Albisetti, Sheng-Chieh Chou, Bulent Zulfikar, Mindy Simpson, Liqi Feng, Helena Palmborg, Graham Neill, Lydia Abad-Franch, Sriya Gunawardena, Karin Fijnvandraat

Available materials

Oral Presentation

Publication

EAHAD •
5 February, 2025 •
•

Real-World Effectiveness and Usage of a Recombinant Factor VIII Fc: Interim Analysis in Adults from the 48-Month Prospective, Observational A-MORE Study

Olga Benitez Hidalgo, Anna Olsson, Karina Meijer, Carmen Escuriola-Ettingshausen, Flora Peyvandi, Andreu Schoenenberger López, Markus Fusser, Stefan Lethagen

Available materials

Poster

Publication

Assessment of treatment schedule, factor VIII trough level, and area under the curve for efanesoctocog alfa vs an extended half-life FVIII comparator: a modelling approach

Efanesoctocog Alfa for the Perioperative Management of Patients with Severe Haemophilia A: 4 years of Experience in the XTEND Clinical Program

Two-Year Clinical Outcomes of Once-Weekly Efanesoctocog Alfa Prophylaxis in Children with Severe Hemophilia A: Second Interim Analysis of the XTEND-ed Phase 3 Study

Real-World Effectiveness and Usage of a Recombinant Factor VIII Fc: Interim Analysis in Adults from the 48-Month Prospective, Observational A-MORE Study

Real-World Effectiveness and Usage of a Recombinant Factor VIII Fc: Interim Analysis in Children and Adolescents from the 48-Month Prospective, Observational A-MORE Study

Major Surgical Outcomes with Efanesoctocog Alfa: 4 Years’ Experience in the XTEND Clinical Program

Long-term observational joint health study in patients initiating efanesoctocog alfa: baseline data

Observational Study of Prophylactic Efanesoctocog Alfa for Joint Health in Hemophilia A: PROTECT-ALT

Joint health outcomes with efanesoctocog alfa in adults/adolescents from XTEND-1 continuing XTEND-ed